Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression?

Yip-Schneider MT, Soufi M, Carr RA, Flick KF, Wu H, Colgate CL, Schmidt CM.

Am J Surg. 2019 Sep 17. pii: S0002-9610(19)30847-5. doi: 10.1016/j.amjsurg.2019.09.013. [Epub ahead of print]

PMID:
31554598
2.

Pancreatic Fluid Interleukin-1β Complements Prostaglandin E2 and Serum Carbohydrate Antigen 19-9 in Prediction of Intraductal Papillary Mucinous Neoplasm Dysplasia.

Simpson RE, Yip-Schneider MT, Flick KF, Wu H, Colgate CL, Schmidt CM.

Pancreas. 2019 Sep;48(8):1026-1031. doi: 10.1097/MPA.0000000000001377.

PMID:
31404023
3.

A multimodality test to guide the management of patients with a pancreatic cyst.

Springer S, Masica DL, Dal Molin M, Douville C, Thoburn CJ, Afsari B, Li L, Cohen JD, Thompson E, Allen PJ, Klimstra DS, Schattner MA, Schmidt CM, Yip-Schneider M, Simpson RE, Fernandez-Del Castillo C, Mino-Kenudson M, Brugge W, Brand RE, Singhi AD, Scarpa A, Lawlor R, Salvia R, Zamboni G, Hong SM, Hwang DW, Jang JY, Kwon W, Swan N, Geoghegan J, Falconi M, Crippa S, Doglioni C, Paulino J, Schulick RD, Edil BH, Park W, Yachida S, Hijioka S, van Hooft J, He J, Weiss MJ, Burkhart R, Makary M, Canto MI, Goggins MG, Ptak J, Dobbyn L, Schaefer J, Sillman N, Popoli M, Klein AP, Tomasetti C, Karchin R, Papadopoulos N, Kinzler KW, Vogelstein B, Wolfgang CL, Hruban RH, Lennon AM.

Sci Transl Med. 2019 Jul 17;11(501). pii: eaav4772. doi: 10.1126/scitranslmed.aav4772.

PMID:
31316009
4.

Multifocal High-Grade Pancreatic Precursor Lesions: A Case Series and Management Recommendations.

Soufi M, Yip-Schneider MT, Carr RA, Roch AM, Wu HH, Schmidt CM.

J Pancreat Cancer. 2019 Apr 29;5(1):8-11. doi: 10.1089/pancan.2019.0001. eCollection 2019.

5.

Response to Comment on Sims et al. Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes. Diabetes Care 2019;42:258-264.

Sims EK, Bahnson HT, Nyalwidhe J, Haataja L, Davis AK, Speake C, DiMeglio LA, Blum J, Morris MA, Mirmira RG, Nadler J, Mastracci TL, Marcovina S, Qian WJ, Yi L, Swensen AC, Yip-Schneider M, Schmidt CM, Considine RV, Arvan P, Greenbaum CJ, Evans-Molina C.

Diabetes Care. 2019 May;42(5):e85-e86. doi: 10.2337/dci19-0012. No abstract available.

PMID:
31010952
6.

Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes.

Sims EK, Bahnson HT, Nyalwidhe J, Haataja L, Davis AK, Speake C, DiMeglio LA, Blum J, Morris MA, Mirmira RG, Nadler J, Mastracci TL, Marcovina S, Qian WJ, Yi L, Swensen AC, Yip-Schneider M, Schmidt CM, Considine RV, Arvan P, Greenbaum CJ, Evans-Molina C; T1D Exchange Residual C-peptide Study Group.

Diabetes Care. 2019 Feb;42(2):258-264. doi: 10.2337/dc17-2625. Epub 2018 Dec 10.

PMID:
30530850
7.

Circulating Thrombospondin-2 enhances prediction of malignant intraductal papillary mucinous neoplasm.

Simpson RE, Yip-Schneider MT, Wu H, Fan H, Liu Z, Korc M, Zhang J, Schmidt CM.

Am J Surg. 2019 Mar;217(3):425-428. doi: 10.1016/j.amjsurg.2018.08.026. Epub 2018 Sep 7.

PMID:
30293901
8.

Clinical criteria for integrated molecular pathology in intraductal papillary mucinous neoplasm: less is more.

Simpson RE, Cockerill NJ, Yip-Schneider MT, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, Al-Haddad MA, Schmidt CM.

HPB (Oxford). 2019 May;21(5):574-581. doi: 10.1016/j.hpb.2018.09.004. Epub 2018 Oct 5.

PMID:
30293868
9.

Circulating Leptin and Branched Chain Amino Acids-Correlation with Intraductal Papillary Mucinous Neoplasm Dysplastic Grade.

Yip-Schneider MT, Simpson R, Carr RA, Wu H, Fan H, Liu Z, Korc M, Zhang J, Schmidt CM.

J Gastrointest Surg. 2019 May;23(5):966-974. doi: 10.1007/s11605-018-3963-y. Epub 2018 Sep 13.

PMID:
30215202
10.

DNA profile components predict malignant outcomes in select cases of intraductal papillary mucinous neoplasm with negative cytology.

Simpson RE, Cockerill NJ, Yip-Schneider MT, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, Al-Haddad MA, Schmidt CM.

Surgery. 2018 Oct;164(4):712-718. doi: 10.1016/j.surg.2018.05.033. Epub 2018 Aug 20.

PMID:
30139561
11.

A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer.

Fahrmann JF, Bantis LE, Capello M, Scelo G, Dennison JB, Patel N, Murage E, Vykoukal J, Kundnani DL, Foretova L, Fabianova E, Holcatova I, Janout V, Feng Z, Yip-Schneider M, Zhang J, Brand R, Taguchi A, Maitra A, Brennan P, Max Schmidt C, Hanash S.

J Natl Cancer Inst. 2019 Apr 1;111(4):372-379. doi: 10.1093/jnci/djy126.

12.

Pancreatic cyst fluid glucose: rapid, inexpensive, and accurate diagnosis of mucinous pancreatic cysts.

Carr RA, Yip-Schneider MT, Simpson RE, Dolejs S, Schneider JG, Wu H, Ceppa EP, Park W, Schmidt CM.

Surgery. 2018 Mar;163(3):600-605. doi: 10.1016/j.surg.2017.09.051. Epub 2017 Dec 11.

PMID:
29241991
13.

Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers.

Cohen JD, Javed AA, Thoburn C, Wong F, Tie J, Gibbs P, Schmidt CM, Yip-Schneider MT, Allen PJ, Schattner M, Brand RE, Singhi AD, Petersen GM, Hong SM, Kim SC, Falconi M, Doglioni C, Weiss MJ, Ahuja N, He J, Makary MA, Maitra A, Hanash SM, Dal Molin M, Wang Y, Li L, Ptak J, Dobbyn L, Schaefer J, Silliman N, Popoli M, Goggins MG, Hruban RH, Wolfgang CL, Klein AP, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Lennon AM.

Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10202-10207. doi: 10.1073/pnas.1704961114. Epub 2017 Sep 5.

14.

Prostaglandin E2: A Pancreatic Fluid Biomarker of Intraductal Papillary Mucinous Neoplasm Dysplasia.

Yip-Schneider MT, Carr RA, Wu H, Schmidt CM.

J Am Coll Surg. 2017 Oct;225(4):481-487. doi: 10.1016/j.jamcollsurg.2017.07.521. Epub 2017 Jul 21.

15.

Pancreatic Cyst Fluid Vascular Endothelial Growth Factor A and Carcinoembryonic Antigen: A Highly Accurate Test for the Diagnosis of Serous Cystic Neoplasm.

Carr RA, Yip-Schneider MT, Dolejs S, Hancock BA, Wu H, Radovich M, Schmidt CM.

J Am Coll Surg. 2017 May 18. pii: S1072-7515(17)30452-0. doi: 10.1016/j.jamcollsurg.2017.05.003. [Epub ahead of print]

16.

Global Protease Activity Profiling Provides Differential Diagnosis of Pancreatic Cysts.

Ivry SL, Sharib JM, Dominguez DA, Roy N, Hatcher SE, Yip-Schneider MT, Schmidt CM, Brand RE, Park WG, Hebrok M, Kim GE, O'Donoghue AJ, Kirkwood KS, Craik CS.

Clin Cancer Res. 2017 Aug 15;23(16):4865-4874. doi: 10.1158/1078-0432.CCR-16-2987. Epub 2017 Apr 19.

17.

Factors influencing the cytotoxicity of α-methylene-γ-hydroxy esters against pancreatic cancer.

Ramachandran PV, Helppi MA, Lehmkuhler AL, Marchi JM, Schmidt CM, Yip-Schneider MT.

Bioorg Med Chem Lett. 2015 Oct 1;25(19):4270-3. doi: 10.1016/j.bmcl.2015.07.087. Epub 2015 Jul 30.

PMID:
26264501
18.

A combination of molecular markers and clinical features improve the classification of pancreatic cysts.

Springer S, Wang Y, Dal Molin M, Masica DL, Jiao Y, Kinde I, Blackford A, Raman SP, Wolfgang CL, Tomita T, Niknafs N, Douville C, Ptak J, Dobbyn L, Allen PJ, Klimstra DS, Schattner MA, Schmidt CM, Yip-Schneider M, Cummings OW, Brand RE, Zeh HJ, Singhi AD, Scarpa A, Salvia R, Malleo G, Zamboni G, Falconi M, Jang JY, Kim SW, Kwon W, Hong SM, Song KB, Kim SC, Swan N, Murphy J, Geoghegan J, Brugge W, Fernandez-Del Castillo C, Mino-Kenudson M, Schulick R, Edil BH, Adsay V, Paulino J, van Hooft J, Yachida S, Nara S, Hiraoka N, Yamao K, Hijioka S, van der Merwe S, Goggins M, Canto MI, Ahuja N, Hirose K, Makary M, Weiss MJ, Cameron J, Pittman M, Eshleman JR, Diaz LA Jr, Papadopoulos N, Kinzler KW, Karchin R, Hruban RH, Vogelstein B, Lennon AM.

Gastroenterology. 2015 Nov;149(6):1501-10. doi: 10.1053/j.gastro.2015.07.041. Epub 2015 Aug 4.

19.

Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.

Waters JA, Matos J, Yip-Schneider M, Aguilar-Saavedra JR, Crean CD, Beane JD, Dumas RP, Suvannasankha A, Schmidt CM.

Surgery. 2015 Oct;158(4):881-8; discussion 888-9. doi: 10.1016/j.surg.2015.04.043. Epub 2015 Jul 21.

PMID:
26209568
20.

Vascular endothelial growth factor: in reply to Giorgakis and colleagues.

Yip-Schneider M, Schmidt CM.

J Am Coll Surg. 2014 Sep;219(3):591-2. doi: 10.1016/j.jamcollsurg.2014.06.009. No abstract available.

PMID:
25151349
21.

Vascular endothelial growth factor, a novel and highly accurate pancreatic fluid biomarker for serous pancreatic cysts.

Yip-Schneider MT, Wu H, Dumas RP, Hancock BA, Agaram N, Radovich M, Schmidt CM.

J Am Coll Surg. 2014 Apr;218(4):608-17. doi: 10.1016/j.jamcollsurg.2013.12.019. Epub 2013 Dec 24.

PMID:
24491241
22.

Synthetic α-(aminomethyl)-γ-butyrolactones and their anti-pancreatic cancer activities.

Ramachandran PV, Nicponski DR, Nair HN, Helppi MA, Gagare PD, Schmidt CM, Yip-Schneider MT.

Bioorg Med Chem Lett. 2013 Dec 15;23(24):6911-4. doi: 10.1016/j.bmcl.2013.09.065. Epub 2013 Sep 30.

PMID:
24176399
23.

Alcohol activates the hedgehog pathway and induces related procarcinogenic processes in the alcohol-preferring rat model of hepatocarcinogenesis.

Chan IS, Guy CD, Machado MV, Wank A, Kadiyala V, Michelotti G, Choi S, Swiderska-Syn M, Karaca G, Pereira TA, Yip-Schneider MT, Max Schmidt C, Diehl AM.

Alcohol Clin Exp Res. 2014 Mar;38(3):787-800. doi: 10.1111/acer.12279. Epub 2013 Oct 24.

24.

The first synthesis of a borylated α-methylene-γ-butyrolactone.

Ramachandran PV, Nicponski DR, Drolet MP, Schmidt CM, Yip-Schneider MT.

Future Med Chem. 2013 Apr;5(6):633-9. doi: 10.4155/fmc.13.37.

PMID:
23617427
25.

Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer.

Yip-Schneider MT, Wu H, Stantz K, Agaram N, Crooks PA, Schmidt CM.

BMC Cancer. 2013 Apr 17;13:194. doi: 10.1186/1471-2407-13-194.

26.

Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer.

Yip-Schneider MT, Wu H, Hruban RH, Lowy AM, Crooks PA, Schmidt CM.

Pancreas. 2013 Jan;42(1):160-7. doi: 10.1097/MPA.0b013e318254f455.

PMID:
22699205
27.

Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells.

Holcomb BK, Yip-Schneider MT, Waters JA, Beane JD, Crooks PA, Schmidt CM.

J Gastrointest Surg. 2012 Jul;16(7):1333-40. doi: 10.1007/s11605-012-1913-7. Epub 2012 May 23.

PMID:
22618517
28.

The proteome of normal pancreatic juice.

Doyle CJ, Yancey K, Pitt HA, Wang M, Bemis K, Yip-Schneider MT, Sherman ST, Lillemoe KD, Goggins MD, Schmidt CM.

Pancreas. 2012 Mar;41(2):186-94. doi: 10.1097/MPA.0b013e31822862f6.

29.

Alcohol induces liver neoplasia in a novel alcohol-preferring rat model.

Yip-Schneider MT, Doyle CJ, McKillop IH, Wentz SC, Brandon-Warner E, Matos JM, Sandrasegaran K, Saxena R, Hennig ME, Wu H, Waters JA, Klein PJ, Froehlich JC, Schmidt CM.

Alcohol Clin Exp Res. 2011 Dec;35(12):2216-25. doi: 10.1111/j.1530-0277.2011.01568.x. Epub 2011 Jul 25.

30.

Transforming growth factor α levels in pancreatic fluid.

Doyle CJ, Agaram NP, Yip-Schneider MT, Schmidt CM.

Pancreas. 2011 Mar;40(2):260-4.

PMID:
21404459
31.

Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers.

Yang Y, Liu H, Li Z, Zhao Z, Yip-Schneider M, Fan Q, Schmidt CM, Chiorean EG, Xie J, Cheng L, Chen JH, Zhang JT.

Int J Biochem Mol Biol. 2011 Jan 1;2(1):89-98.

32.

Role of 14-3-3σ in poor prognosis and in radiation and drug resistance of human pancreatic cancers.

Li Z, Dong Z, Myer D, Yip-Schneider M, Liu J, Cui P, Schmidt CM, Zhang JT.

BMC Cancer. 2010 Nov 1;10:598. doi: 10.1186/1471-2407-10-598.

33.

Tailored α-methylene-γ-butyrolactones and their effects on growth suppression in pancreatic carcinoma cells.

Ramachandran PV, Pratihar D, Nair HN, Walters M, Smith S, Yip-Schneider MT, Wu H, Schmidt CM.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6620-3. doi: 10.1016/j.bmcl.2010.09.022. Epub 2010 Sep 21. Erratum in: Bioorg Med Chem Lett. 2011 Jan 15;21(2):880.

PMID:
20888222
34.

Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems.

Hennig M, Yip-Schneider MT, Wentz S, Wu H, Hekmatyar SK, Klein P, Bansal N, Schmidt CM.

Hepatology. 2010 Apr;51(4):1218-25. doi: 10.1002/hep.23470.

PMID:
20112426
35.

Sulindac prevents carcinogen-induced intrahepatic cholangiocarcinoma formation in vivo.

Wentz SC, Yip-Schneider MT, Gage EA, Saxena R, Badve S, Schmidt CM.

J Surg Res. 2009 Nov;157(1):e87-95. doi: 10.1016/j.jss.2008.10.006. Epub 2008 Nov 7.

PMID:
19564027
36.

Natural and synthetic α,β-unsaturated carbonyls for NF-κB inhibition.

Ramachandran PV, Yip-Schneider M, Schmidt CM.

Future Med Chem. 2009 Apr;1(1):179-200. doi: 10.4155/fmc.09.15. Review.

PMID:
21426075
37.

Ethanol-TGFalpha-MEK signaling promotes growth of human hepatocellular carcinoma.

Hennig M, Yip-Schneider MT, Klein P, Wentz S, Matos JM, Doyle C, Choi J, Wu H, O'Mara A, Menze A, Noble S, McKillop IH, Schmidt CM.

J Surg Res. 2009 Jun 15;154(2):187-95. doi: 10.1016/j.jss.2008.11.836. Epub 2008 Dec 13.

38.

Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.

Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM.

J Pharmacol Exp Ther. 2009 Jun;329(3):1063-70. doi: 10.1124/jpet.108.147306. Epub 2009 Mar 3.

PMID:
19258520
39.

Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer.

Yip-Schneider MT, Wu H, Njoku V, Ralstin M, Holcomb B, Crooks PA, Neelakantan S, Sweeney CJ, Schmidt CM.

Pancreas. 2008 Oct;37(3):e45-53. doi: 10.1097/MPA.0b013e318172b4dd.

PMID:
18815538
40.

The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.

Choi J, Yip-Schneider M, Albertin F, Wiesenauer C, Wang Y, Schmidt CM.

J Surg Res. 2008 Dec;150(2):219-26. doi: 10.1016/j.jss.2008.01.029. Epub 2008 Mar 3.

PMID:
18468633
41.

The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy.

Holcomb B, Yip-Schneider M, Schmidt CM.

Pancreas. 2008 Apr;36(3):225-35. doi: 10.1097/MPA.0b013e31815b3207. Review.

PMID:
18362834
42.

Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies.

Holcomb B, Yip-Schneider MT, Matos JM, Dixon J, Kennard J, Mahomed J, Shanmugam R, Sebolt-Leopold J, Schmidt CM.

J Gastrointest Surg. 2008 Feb;12(2):288-96. Epub 2007 Nov 30.

PMID:
18049840
43.

PGE(2) in pancreatic cyst fluid helps differentiate IPMN from MCN and predict IPMN dysplasia.

Schmidt CM, Yip-Schneider MT, Ralstin MC, Wentz S, DeWitt J, Sherman S, Howard TJ, McHenry L, Dutkevitch S, Goggins M, Nakeeb A, Lillemoe KD.

J Gastrointest Surg. 2008 Feb;12(2):243-9. Epub 2007 Nov 20.

PMID:
18027059
44.

Targeting MEK is effective chemoprevention of hepatocellular carcinoma in TGF-alpha-transgenic mice.

Wentz SC, Wu H, Yip-Schneider MT, Hennig M, Klein PJ, Sebolt-Leopold J, Schmidt CM.

J Gastrointest Surg. 2008 Jan;12(1):30-7. Epub 2007 Nov 7.

PMID:
17987349
45.

Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancer.

Vegeler RC, Yip-Schneider MT, Ralstin M, Wu H, Crooks PA, Neelakantan S, Nakshatri H, Sweeney CJ, Schmidt CM.

J Surg Res. 2007 Nov;143(1):169-76. Epub 2007 Aug 31.

PMID:
17950089
46.

Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo.

Yip-Schneider MT, Wu H, Ralstin M, Yiannoutsos C, Crooks PA, Neelakantan S, Noble S, Nakshatri H, Sweeney CJ, Schmidt CM.

Mol Cancer Ther. 2007 Jun;6(6):1736-44. Epub 2007 May 31. Erratum in: Mol Cancer Ther. 2007 Oct;6(10):2816.

47.

Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model.

Shanmugam R, Jayaprakasan V, Gokmen-Polar Y, Kelich S, Miller KD, Yip-Schneider M, Cheng L, Bhat-Nakshatri P, Sledge GW Jr, Nakshatri H, Zheng QH, Miller MA, DeGrado T, Hutchins GD, Sweeney CJ.

Prostate. 2006 Oct 1;66(14):1498-511.

PMID:
16921510
48.

Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia.

Crowell PL, Schmidt CM, Yip-Schneider MT, Savage JJ, Hertzler DA 2nd, Cummings WO.

Neoplasia. 2006 Jun;8(6):437-45.

49.

Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest.

Ralstin MC, Gage EA, Yip-Schneider MT, Klein PJ, Wiebke EA, Schmidt CM.

Mol Cancer Res. 2006 Jun;4(6):387-99.

50.

The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer.

Klein PJ, Schmidt CM, Wiesenauer CA, Choi JN, Gage EA, Yip-Schneider MT, Wiebke EA, Wang Y, Omer C, Sebolt-Leopold JS.

Neoplasia. 2006 Jan;8(1):1-8.

Supplemental Content

Loading ...
Support Center